The phase I NiCOL trial (NCT03298893) [52] explored the anti-PD-1 nivolumab concurrent and following CCRT in 21 patients with stages IB2 to IVA locally advanced cervical cancer, regardless of lymph node status. Here, PDCD1 is linked to cervical carcinoma.